References

  1. FDA summary of safety and effectiveness data (SSED). TriVisc®

  2. TriVisc Package Insert

  3. Ulucay, I. et al. Acta Orthop Traumatol Turc 2007;41: 337-342. The use of arthroscopic debridement and viscosupplementation in knee osteoarthritis.

  4. Dıraçöglu, D. et al. J Back and Musculo Rehab. 2016;16: 53. Single versus multiple dose hyaluronic acid: Comparison of the results.

Euflexxa® is a registered trademark of Ferring B.V. LLC.
VISCO-3® and Supartz® are trademarks of Seikagaku Corporation.

† The Adant® formulation is approved in 63 countries outside the US. Adant is manufactured by TEDEC-MEIJI FARMA and is authorized to be marketed and distributed under the trademark TriVisc.